9 results
10-K
2020 FY
NEXI
Neximmune Inc
31 Mar 21
Annual report
4:02pm
become obsolete before we recoup any portion of our related research and development and commercialization expenses. Competition … to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product
424B4
NEXI
Neximmune Inc
16 Feb 21
Prospectus supplement with pricing info
4:38pm
of competition. As a result, our actual or proposed immunotherapies could become obsolete before we recoup any portion of our related research and development … . Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain
S-1/A
hci8v0cmmxct1m h9hm
8 Feb 21
IPO registration (amended)
7:29am
S-1
l12d a08xq2lxs
19 Jan 21
IPO registration
4:38pm
DRS/A
vcxe64tyf8491iqhag
15 Jan 21
Draft registration statement (amended)
12:00am
DRS
mn14n21n
14 Dec 20
Draft registration statement
12:00am
- Prev
- 1
- Next